Overcoming antigen loss in CAR T therapy with Vγ9Vδ2 CAR T-cells
{{output}}
Background: Vγ9Vδ2 T-cells demonstrate potent antitumor activity in vitro but, despite successful safety studies, the clinical benefit of Vγ9Vδ2 in adoptive cell therapy has been limited. One approach to enhance the therapeut... ...
